TheraCryf are leading the development of novel medicines in oncology and behavioural brain diseases with high unmet clinical needs.
Following the acquisition of a peer, and name change from Evgen Pharma to TheraCryf, we continued to develop our reporting relationship with TheraCryf, working closely with their internal team, helping them to progress their annual report – strengthening their story and key messages, developing clearer strategies for them to be able to tell their story effectively.